Imazol (Clotrimazole)

Clotrimazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in the synthesis of ergosterol, which is essential for fungal cell‑membrane integrity. By preventing ergosterol formation, the drug disrupts membrane structure, increases permeability, halts fungal growth and ultimately leads to cell death. The action is selective for fungal cells, limiting effects on human tissues.

The dosing schedule for Imazol is determined by the prescribing healthcare professional based on the infection type, location and severity. Generally, a thin layer of the topical preparation is applied to the affected area once or twice daily for the period recommended by the prescriber, often ranging from one to four weeks. Patients should follow the exact instructions provided on the label or by their clinician.

Safety data for clotrimazole use during pregnancy and lactation are limited. Because systemic absorption from topical use is minimal, the product is sometimes considered low risk, but definitive conclusions cannot be drawn. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the benefits and potential risks with their healthcare provider before using Imazol.

To place an order for Imazol, visit the product page on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Both Imazol (clotrimazole) and terbinafine belong to different antifungal classes; clotrimazole is an azole, while terbinafine is an allylamine. Clotrimazole works by inhibiting ergosterol synthesis, whereas terbinafine blocks squalene epoxidase, another step in the same pathway. Clinically, both are effective for dermatophyte infections, but terbinafine often requires once‑daily dosing and may have a slightly faster cure rate for certain tinea infections. Choice depends on physician preference, patient tolerance and specific infection characteristics.

Imazol should be stored at room temperature, typically below 25 °C (77 °F). Keep the product in its original packaging to protect it from moisture, light and excessive heat. Do not freeze the preparation, and ensure the container is tightly closed when not in use to maintain stability and potency.

Before applying Imazol, wash and gently dry the affected skin area. Apply a thin, even layer of the topical preparation to the lesion and a small margin of surrounding skin, usually once or twice daily as directed by the prescriber. Allow the medication to dry completely before covering the area with clothing or bandages, unless otherwise instructed.

While most users experience only mild local reactions, rare but serious adverse events can occur. These include allergic contact dermatitis presenting as severe swelling, blistering or hives, and angioedema affecting the face, lips or tongue. In extremely uncommon cases, severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis have been reported. Any signs of extensive rash, swelling or systemic symptoms should prompt immediate medical evaluation.

Imazol should be avoided in individuals with a known hypersensitivity to clotrimazole or any other component of the formulation. It is also not recommended for use on broken, severely inflamed or infected skin without medical supervision, and should not be applied to infants younger than one month of age because safety has not been established for this group.